The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 462.50
Bid: 455.00
Ask: 470.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.297%)
Open: 462.50
High: 462.50
Low: 462.50
Prev. Close: 462.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

China Licence received

12 May 2011 08:00

RNS Number : 4596G
Tristel PLC
12 May 2011
 



Tristel plc

("Tristel" or "the Company")

AIM: TSTL

 

Licence to sell Stella decontamination system received in China

 

Tristel plc, the manufacturer of infection control, contamination control and hygiene products, announces that it has received the administrative licence that will enable the use of its Stella decontamination system in China.

 

Stella is a sophisticated micro-processor controlled tray in which medical instruments are immersed in Tristel's chlorine dioxide disinfectant. Hospitals can employ Stella at a fraction of the capital and running cost of the endoscope washers that are widely used as the only alternative to the age-old practice of placing instruments in a sink or simple plastic container.

 

Stella is particularly relevant to hospital departments such as urology, gynaecology, respiratory, cardiology and GI physiology. It deliberately cannot be used with the large flexible endoscopic instruments that are the focus of most of Tristel's competitors.

 

Tristel received regulatory approval for Stella last Autumn and the receipt of the licence enables its use by hospitals. The Company's China subsidiary, Shanghai Stella Medical Equipment Co. Ltd., has already appointed six distributors for the Stella system. These distributors purchased 30 Stella units between June and December 2010 for training and evaluation purposes. The Company has established its own sales force to sell directly in the Shanghai metropolitan area.

 

Outside of China, Tristel has sold 63 Stella units in the United Kingdom, Belgium, Spain, Ireland, Italy, Dubai, New Zealand and Germany. In a clinical study recently concluded Stella has been subjected to a randomised single-blind comparison with the world's leading brand of instrument disinfectant used in one of the most widely used endoscope washers. Stella's efficacy has been shown to be the equivalent of the process to which it was compared, but it produced vast savings in cost and process time. The study is anticipated to be published later this year.

 

Paul Swinney, Chief Executive of Tristel, said: "We have been eagerly awaiting receipt of this licence for many months because Stella sales in China had been forecast to be a major contributor to our top-line growth this year. Our team in Shanghai will now make every effort to close as much business as possible although our year end is approaching fast. We are confident that the market in China will play an important part in next year's business plan and to this end I am pleased to report that our Tristel Jet product for hard surface disinfection has also been approved by the regulatory body. We have now entered the administrative licence process for this product. Our Wipes System is also in the process of being presented for regulatory approval."

 

Tristel plc

Paul Swinney, Chief Executive

Tel: 01638 721 500

finnCap

Geoff Nash / Charlotte Stranner (Corporate Finance)

Simon Starr (broking)

Tel: 020 7600 1658

Walbrook PR

Tel: 020 7933 8780

Paul McManus (Media Relations)

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Relations)

Mob: 07866 384 707

paul.cornelius@walbrookir.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFDSMEFFSEII
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.